Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6088 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | AZD6088 oral solution |
| B | EXPERIMENTAL | Placebo oral solution |
| Name | Type | Description |
|---|---|---|
| AZD6088 | DRUG | Oral solution. Each subject will receive a single-dose of AZD6088. |
| Placebo | DRUG | Oral solution. Each subject will receive a single-dose of placebo. |
Inclusion Criteria: * Caucasian male and non-fertile female healthy volunteers aged ≥18 to ≤55 years with suitable veins for cannulation or repeated venipuncture. * Clinically normal physical findings including supine BP, pulse rate, ECG and laboratory assessments in relation to age, as judged by t...
AZD6088 is an investigational small molecule being studied in healthy volunteers. It is in Phase 1 clinical development and has not been approved for any medical use. The drug is being evaluated in a clinical trial to assess its safety and tolerability.
AZD6088 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical research on this investigational small molecule drug.
AZD6088 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a clinical trial involving healthy volunteers to evaluate its safety profile.
AZD6088 has one completed clinical trial, identified as NCT00931541, titled "AZD6088 Single Ascending Dose Study." This Phase 1 trial enrolled 35 participants in the United Kingdom and was a randomized, double-blind, controlled study involving healthy volunteers aged 18 years and older.
AZD6088 is the primary name used for this investigational drug in clinical research. No alternative names have been reported for this compound in the available clinical trial information.